On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE ... at risk of rapid disease progression. In ...

A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval ... them a Novartis drug recently awarded accelerated approval.

Novartis NVS said it received accelerated approval from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney ...

The FDA has converted ... measure of kidney function, with elevated levels being associated with serious kidney disease. The drug was the first non-immunosuppressive drug approved for IgAN ...

Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the ...

The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...

An FDA advisory committee has ... drugmaker's data on bardoxolone – a drug for kidney disease – did not show it is effective. Reata is seeking approval from the US regulator for bardoxolone ...

Travere Therapeutics TVTX announced that the FDA ... approval to its oral non-immunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney disease.

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

Patients will be able to get a 10 minute injection of the Roche drug, instead of an hours-long infusion. Novartis already has ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...